BioSpace News Archive

Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive Officer, will be presenting at the Emerging Growth Conference on June 23, 2021.

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that BRUKINSA® (zanubrutinib) has received conditional approval from the China National Medical Products Administration

The European Commission (EC) has approved Aubagio® (teriflunomide) for the treatment of pediatric patients 10 to 17 years of age with relapsing-remitting multiple sclerosis (RRMS).

Happiness Biotech Group Limited announced today that the Company launched the beta version of official site of Happy Buy International.

Teligent, Inc. announced today that its Annual Meeting of Stockholders, scheduled for June 18, 2021, was convened and adjourned without any business being conducted due to the fact that there were not sufficient votes to approve all of the proposals presented.

Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of company information on Neuromyelitis Optica Spectrum Disorder (NMOSD) in three oral sessions during the 7th Congress of the European Academy of Neurology (EAN), June 19 -22, 2021.

Roche today announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for the cobas® SARS-CoV-2 Nucleic acid test.

TG Therapeutics, Inc. today announced the presentation of data from the ULTIMATE I & II global, active controlled, Phase 3 trials evaluating ublituximab.

According to our new market research study on “Bovine Pericardial Valve Market to 2027 - Global Analysis and Forecast by Valve Type Alloy, and End User, the market is expected to reach US$ 4,134.4 million by 2027 from US$ 1,959.7millionin 2019; it is estimated to grow at a CAGR of 9.9% from 2020 to 2027.

Vertex Pharmaceuticals (Canada) Incorporated (NASDAQ: VRTX) today announced Health Canada has granted Marketing Authorization for PrTRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of cystic fibrosis (CF) in people ages 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene,